Effect of Palm Olein Intake on Lipid Profile and Fat Deposition

Launched by IMPERIAL COLLEGE LONDON · Sep 7, 2016

Keywords

ClinConnect Summary

Design: Randomized, parallel design over 14 weeks including a 2 week standardization period and 12 week supplementation. In the standardization period all participants will incorporate palm oil into their diet which will make up 20% of their calories providing a baseline measure. In the supplementation period of 12 weeks, each volunteer will be randomized into one of the three fats: palm olein, interesterified palm olein or soybean oil, consuming 20% of their calories from these fast and remaining 10% fat calories from fats naturally occurring in foods like meat and nuts. Otherwise particip...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Phase I: 30 healthy volunteers (male and female), of all ethnicities, aged 18-60 years, with a body mass index (BMI) of 18.5-25kg/m2.
• • Phase II: 30 healthy volunteers (male and female), of all ethnicities, aged 18-60 years, with a BMI of 25-29.9kg/m2.
• Exclusion Criteria:
• • Following a high fat diet (more than 40% calories coming from fat)
• • Abnormal liver function test (elevated alanine aminotransferase and aspartate transaminase)/ abnormal kidney function test (elevated plasma creatinine)
• • History of type 2 diabetes mellitus, cancer, stomach ulcers, drug abuse or alcoholism, gastrointestinal disorders like Crohn's disease
• • Smokers
• • On lipid/blood pressure- lowering medication/supplements
• • Blood pressure\>140/90 mm Hg
• • Fasting total cholesterol \> 6.2 mmol/L
• • Fasting triacylglyceride \> 2.0 mmol/L
• • Candidates who are going abroad during the planned schedule for the dietary intervention
• • Subject must not be allergic to intervention
• • Pregnancy and breastfeeding (pregnancy test will be undertaken at the screening visit)
• • Subjects taking nutritional supplements or on any weight-loss programs
• • Subjects who gained or lost ≥ 3kg weight in the past three months
• • Female subjects were not on oral contraceptives.
• • Subjects with history of hypo- and hyperthyroidism
• • Claustrophobia
• • Metal implants for example cardiac pacemakers and join replacement